Semaglutide mimicks the effects of GLP-1 Semaglutide was approved by the FDA in 2017 and has since become a popular choice for the management of type 2 diabetes
When a peptide reaches its target cell, it locks into a receptor like a key fitting into a lock, sending a signal that tells the cell to perform a specific action-whether thats building muscle tissue, reducing inflammation, accelerating fat loss, or improving sleep quality
It addresses unwanted fat pockets, letting you enjoy smoother and better-proportioned thighs
Patient-specific factors include age (older adults have more fragile blood vessels and thinner skin), genetic predisposition to easy bruising, nutritional status, and underlying medical conditions affecting coagulation or vascular integrity
Tirzepatide is processed primarily by the liver and doesn't directly stress the kidneys, though GLP-1 medications can affect kidney function markers in people with certain conditions